[Vaccination: cost-effectiveness ratio].
Vaccination is often recognized as having an excellent cost-effectiveness ratio. Economic assessments are more and more important regarding the steadily increasing costs of vaccines. However, vaccine-specific features have to be taken in account and there is scope for improving quality of available economic evaluations of vaccination programmes. To provide clear and concise guidance for improving quality of cost-effectiveness studies in vaccinology, WHO guide has been developed. After presenting this guide, the economic evaluations of the new vaccines introduced in the Belgium calendar are reviewed.
Swennen
B
B
Département d'Epidémiologie et de Médecine Préventive, Unité d'Epidémiologie Pédiatrique et de Vaccination, Ecole de Santé Publique, U.L.B, Bruxelles. bswennen@ulb.ac.be
D001428:Bacterial Vaccines / Q000191:economics / Q000592:standards; D001530:Belgium; D003362:Cost-Benefit Analysis; D006801:Humans; D014611:Vaccination / Q000191:economics* / Q000592:standards; D014612:Vaccines / Q000191:economics* / Q000592:standards; D014765:Viral Vaccines / Q000191:economics / Q000592:standards; D014944:World Health Organization
D001428:Bacterial Vaccines; D014612:Vaccines; D014765:Viral Vaccines